These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2885337)

  • 1. Somatostatin does not alter insulin-mediated glucose disposal.
    Meneilly GS; Elahi D; Minaker KL; Rowe JW
    J Clin Endocrinol Metab; 1987 Aug; 65(2):364-7. PubMed ID: 2885337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin enhances insulin-mediated glucose disposal in elderly subjects.
    Meneilly GS; Elahi D; Minaker KL; Rowe JW
    J Clin Endocrinol Metab; 1988 Aug; 67(2):407-10. PubMed ID: 2899090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin infusion enhances hepatic glucose production during hyperglucagonemia.
    Meneilly GS; Minaker KL; Elahi D; Rowe JW
    Metabolism; 1988 Mar; 37(3):252-6. PubMed ID: 2893970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency.
    Nair KS
    J Clin Endocrinol Metab; 1987 May; 64(5):896-901. PubMed ID: 2881943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impairment of noninsulin-mediated glucose disposal in the elderly.
    Meneilly GS; Elahi D; Minaker KL; Sclater AL; Rowe JW
    J Clin Endocrinol Metab; 1989 Mar; 68(3):566-71. PubMed ID: 2563735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dawn phenomenon does not occur in normal elderly subjects.
    Meneilly GS; Elahi D; Minaker KL; Rowe JW
    J Clin Endocrinol Metab; 1986 Aug; 63(2):292-6. PubMed ID: 3522617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.
    Larsson H; Holst JJ; Ahrén B
    Acta Physiol Scand; 1997 Aug; 160(4):413-22. PubMed ID: 9338524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man.
    Ward WK; Best JD; Halter JB; Porte D
    J Clin Endocrinol Metab; 1984 Mar; 58(3):449-53. PubMed ID: 6141177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin enhances insulin-stimulated glucose uptake in the perfused human forearm.
    Møller N; Bagger JP; Schmitz O; Jørgensen JO; Ovesen P; Møller J; Alberti KG; Orskov H
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1789-93. PubMed ID: 7775624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of somatostatin on the hepatic extraction of insulin and glucagon in the anesthetized dog.
    Ishida T; Röjdmark S; Bloom G; Chou MC; Field JB
    Endocrinology; 1980 Jan; 106(1):220-30. PubMed ID: 7349954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pancreatic glucagon and C-peptide secretion during hyperinsulinemia in euglycemic glucose clamp with or without somatostatin infusion in normal man.
    Wu MS; Ho LT
    Horm Metab Res; 1987 Jun; 19(6):253-6. PubMed ID: 2887501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for an augmented glucagon dependence of hepatic glucose production in cirrhosis of the liver.
    Keller U; Sonnenberg GE; Burckhardt D; Perruchoud A
    J Clin Endocrinol Metab; 1982 May; 54(5):961-8. PubMed ID: 6120952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapancreatic effect of somatostatin infusion to increase glucose clearance.
    Bergman RN; Ader M; Finegood DT; Pacini G
    Am J Physiol; 1984 Sep; 247(3 Pt 1):E370-9. PubMed ID: 6148014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ketone bodies on glucose production and utilization in the miniature pig.
    Müller MJ; Paschen U; Seitz HJ
    J Clin Invest; 1984 Jul; 74(1):249-61. PubMed ID: 6376544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between insulin-mediated glucose disposal by muscle and adipose tissue lipolysis in healthy volunteers.
    Pei D; Chen YD; Hollenbeck CB; Bhargava R; Reaven GM
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3368-72. PubMed ID: 7593453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective suppression of hepatic glucose output by human proinsulin in the dog.
    Lavelle-Jones M; Scott MH; Kolterman O; Rubenstein AH; Olefsky JM; Moossa AR
    Am J Physiol; 1987 Feb; 252(2 Pt 1):E230-6. PubMed ID: 2881485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A-Cell and gut glucagon in normal and depancreatized dogs. Inhibition by somatostatin and insulin.
    Matsuyama T; Wider MD; Tanaka R; Shima K; Tarui S; Nishikawa M; Foà PP
    Diabete Metab; 1979 Jun; 5(2):141-7. PubMed ID: 478084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of insulin resistance in Turner syndrome.
    Stoppoloni G; Prisco F; Alfano C; Iafusco D; Marrazzo G; Paolisso G
    Diabete Metab; 1990; 16(4):267-71. PubMed ID: 1979950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects.
    Prager R; Wallace P; Olefsky JM
    J Clin Invest; 1986 Aug; 78(2):472-81. PubMed ID: 3525609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon and glucose tolerance in liver cirrhosis.
    Greco AV; Altomonte L; Ghirlanda G; D'Anna LM; Manna R; Caputo S; Uccioli L
    Acta Endocrinol (Copenh); 1988 Jul; 118(3):337-45. PubMed ID: 2899368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.